Literature DB >> 9363804

Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

B J Cummings1, C J Pike, R Shankle, C W Cotman.   

Abstract

The relationship between progressive cognitive decline and underlying neuropathology associated with Alzheimer s disease (AD) is a key issue in defining the mechanisms responsible for functional loss. This has been a subject of much controversy, with separate studies comparing various clinical and neuropathological indices in AD. Further, it is difficult to compare studies with differences in histochemical staining protocols, brain regions examined, and data quantification criteria. There are many difficulties in designing a clinical-pathological correlative study involving AD patients. It is necessary to control for several key parameters. For example, a broad range of cognitively impaired subjects is needed, as well as short postmortem delays, brief intervals between cognitive testing and death, and the most sensitive detection and quantification techniques. In this study, we carefully controlled for each of these parameters to determine if there is a relationship between global cognitive dysfunction and multiple neuropathological indices. We selected 20 individuals representing a broad range of cognitive ability from normal to severely impaired based on the MMSE, Blessed IMC, and CDR. We counted plaque number, NFT number, dystrophic neurite number, and the relative extent of thioflavine positive plaques and neuritic involvement within plaques. We also quantified cortical area occupied by beta-amyloid immunoreactivity (A beta Load) and PHF-1 positive neuropil threads and tangles (PHF Load) using computer-based image analysis. Interestingly, we found that most pathologic measures correlated highly with the severity of dementia. However, the strongest predictor of premortem cognitive dysfunction on all three cognitive measures was the relative area of entorhinal cortex occupied by beta-amyloid deposition. In conclusion, our data show that in a carefully controlled correlative study, a variety of neuropathological variables are strongly correlated with cognitive impairment. Plaque related variables may be as strongly related to cognitive dysfunction as other established measures, including synapse loss, cell death and tau hyperphosphorylation, although no correlative study can demonstrate causality.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9363804     DOI: 10.1016/s0197-4580(96)00170-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  75 in total

1.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Authors:  Rena Li; Kristina Lindholm; Li-Bang Yang; Xu Yue; Martin Citron; Riqiang Yan; Thomas Beach; Lucia Sue; Marwan Sabbagh; Huaibin Cai; Philip Wong; Donald Price; Yong Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

Review 2.  Two-photon imaging of synaptic plasticity and pathology in the living mouse brain.

Authors:  Jaime Grutzendler; Wen-Biao Gan
Journal:  NeuroRx       Date:  2006-10

Review 3.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 4.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.

Authors:  J C Morris; J L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity.

Authors:  Gintaras Valincius; Frank Heinrich; Rima Budvytyte; David J Vanderah; Duncan J McGillivray; Yuri Sokolov; James E Hall; Mathias Lösche
Journal:  Biophys J       Date:  2008-05-30       Impact factor: 4.033

6.  Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology.

Authors:  Michal Schnaider Beeri; Jeremy M Silverman; James Schmeidler; Michael Wysocki; Hillel Z Grossman; Dushyant P Purohit; Daniel P Perl; Vahram Haroutunian
Journal:  Dement Geriatr Cogn Disord       Date:  2008-03-27       Impact factor: 2.959

7.  Anti-amnesic effect of dimemorfan in mice.

Authors:  Hui-Hung Wang; Jyh-Wei Chien; Yueh-Ching Chou; Jyh-Fei Liao; Chieh-Fu Chen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 8.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

Review 9.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

10.  Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.

Authors:  S Lesné; L Kotilinek; K H Ashe
Journal:  Neuroscience       Date:  2007-11-17       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.